Trade INCY

Incyte Corp Ltd

-

00:00:00

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read more...

1D Change

2.467%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

TRADING CONDITIONS

INCY
TRADING CONDITIONS

Digits

2

Point

0.01

Live Spread (Pips)

 

x

Leverage

 
1:5

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-1.62

Swap Short (Points)

-0.94
Available on
MT5, TV, cTrader
Last update at 2024-10-10 20:00:28 GMT+3
*Data Source: MT5 Server Prime Account Pricing

Margin Calculator

Calculation Results

Current Price

65.24

Required Margin

Converted Currency

Required Margin

Account Base Currency

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage. 


The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss. 

 

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value. 


The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate

Swaps Calculator

Calculation Results

65.24

How it works:

Use our swaps calculator to determine the interest rate differential between two assets. 

 

Select your account base currency, an asset pair, the size of your position in lots. 


The calculation is carried out as follows:
Swap = (One Point / Exchange Rate) * Trade Size (Lot Size) * Swap Value in Points

Currency Calculator

Calculation Results

Loading...

How it works:

Use our currency calculator to determine the value of one currency against another, based on current exchange rates.

Join Now